1.
|
The
appointment of Charles Bancroft was made by the Board on the
recommendation of the Nominations Committee.
|
|
2.
|
The
Board determined that Mr Bancroft is an independent Non-Executive
Director on appointment in accordance with the UK Corporate
Governance Code (the Code). He has also been designated as having
recent and relevant financial experience for the purposes of the
Code and as an audit committee financial expert as defined in rules
promulgated under the Sarbanes-Oxley Act of 2002.
|
|
3.
|
He will
receive the standard basic fee for a Non-Executive Director of
£95,000 per annum and when he succeeds Ms Lewent as Chair of
the Audit & Risk Committee, he will receive the supplemental
fee of £80,000 per annum. He will be required to invest at
least 25% of his fees in GSK shares that should be held until he
retires from the Board.
|
|
4.
|
Membership
of other Committees will be determined in due course.
|
|
5.
|
Mr
Bancroft does not have a service contract. He has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
|
|
6.
|
There
are no additional details to disclose in respect of Mr Bancroft's
appointment under Listing Rule 9.6.13R.
|
|
7.
|
From 1
May 2020 the Board of GSK will comprise:
|
|
|
Sir
Jonathan Symonds
Emma
Walmsley
Iain
Mackay
Dr Hal
Barron
Vindi
Banga
Charles
Bancroft
Dr
Vivienne
Cox
Lynn
Elsenhans
Dr
Jesse Goodman
Dr
Laurie Glimcher
Judy
Lewent
Urs
Rohner
|
Non-Executive
Chairman
Chief
Executive Officer
Chief
Financial Officer
Chief
Scientific Officer and President, R&D
Senior
Independent Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
|
GSK enquiries:
|
|
|
|
UK
Media enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
Mary
Hinks-Edwards
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
US
Media enquiries:
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
208 047 5194
|
(London)
|
|
Danielle
Smith
|
+44 (0)
20 8047 7562
|
(London)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
20, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|